Subcutaneous semaglutide and peripheral arterial occlusive disease in type 2 diabetes: network meta-analysis of randomized trials
Peripheral arterial occlusive disease (PAOD) outcomes are rarely prespecified in randomised type 2 diabetes trials, limiting comparative inference across glucagon-like peptide-1 receptor agonists (GLP-1RAs). To compare GLP-1RA regimens for PAOD risk in adults with type 2 diabetes. We conducted a PRI...